1-3 of 3
Elaine Willmore, PhD
Close
Sort by
Journal Articles

The p53-MDM2 Antagonist RG7388 Activates p53 and Induces a Predominantly Pro-Apoptotic Gene Expression Signature in Chronic Lymphocytic Leukemia

Carmela Ciardullo, PhD, Laura Woodhouse, PhD, Erhan Aptullahoglu, MSc, Jonathan P Wallis, MD, Helen J Marr, MD PhD, Scott R Marshall, MD, Nick Bown, PhD, Elaine Willmore, PhD, John Lunec, PhD
Journal: Blood
Blood (2016) 128 (22): 893.
https://doi.org/10.1182/blood.V128.22.893.893
Published: 2016
Journal Articles

Targeting Ikkα in CLL: Inhibition of Non-Canonical NF-κb Signaling Decreases Survival and Proliferation of CD40L-Stimulated Primary CLL Cells

Elaine Willmore, PhD, Aaron Gardner, PhD, Susan J Tudhope, PhD, Andrew Herridge, BSc, Jill Hunter, Jonathan P Wallis, MD, Helen J Marr, MD PhD, Giacomo Berretta, PhD, David Breen, PhD, Andrew Paul, PhD, Darren Edwards, PhD, Louise C Young, PhD, Colin J Suckling, PhD, Robin Plevin, PhD, Marie Boyd, PhD, James M Allan, DPhil, Simon Mackay, PhD, Neil D Perkins, PhD
Journal: Blood
Blood (2016) 128 (22): 3959.
https://doi.org/10.1182/blood.V128.22.3959.3959
Published: 2016
Journal Articles

Targeting DNA-PK and ATM Increases Sensitivity to Chlorambucil and Fludarabine in Chemoresistant and p53-Defective B-CLL Cells.

Elaine Willmore, PhD, Geoffrey P. Summerfield, MD, Tryfonia Mainou-Fowler, PhD, Graham H. Jackson, MD, Anthony Carter, Andrew R. Pettitt, MD, Barbara W. Durkacz, PhD
Journal: Blood
Blood (2006) 108 (11): 523.
https://doi.org/10.1182/blood.V108.11.523.523
Published: 2006